Subtype
Brain Neoplasm
CI-CAN-00002030Explore in graph →
Non-malignant511 active trials34 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002030Explore in graph →
Clinical trials
2,117 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06015295 | A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy | terminated | N/A | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03170141 | Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme | terminated | Phase 1 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 24, 2026 | clinicaltrials |
| NCT03173950 | Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers | terminated | Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT05627323 | CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma | terminated | Phase 1 | 1 | Chimeric TherapeuticsINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07050836 | Contrast Enhanced Ultrasound in Neurosurgery to Improve Glioma Visualization and Border Demarcation | terminated | Early Phase 1 | 2 | University of Colorado, DenverOTHER | 1 | Jun 22, 2026 | clinicaltrials |
| NCT04994977 | Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery | terminated | Phase 1 | 1 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT04955743 | Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | terminated | Phase 2 | 18 | Yale UniversityOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05029960 | Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas | terminated | Early Phase 1 | 3 | University of RochesterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT05934630 | Testing Cerebrospinal Fluid for Cell-free Tumor DNA in Children, Adolescents, and Young Adults With Brain Tumors | terminated | — | 57 | Pediatric Brain Tumor ConsortiumNETWORK | 2 | Apr 23, 2026 | clinicaltrials |
| NCT05087888 | MRI and Blood Biomarkers for the Prediction of Neurocognitive Decline Following Brain Radiation | terminated | — | 9 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02565433 | Prospective Assessment of Quality of Life in Patients Treated by Radiosurgery for Brain Metastases (PRAMECE-1302)(PRAMECE) | terminated | N/A | 52 | Centre Oscar LambretOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT02942264 | Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma | terminated | Phase 1 / Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Feb 23, 2026 | clinicaltrials |
| NCT04825275 | Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial | terminated | Early Phase 1 | 7 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT06193174 | Re-Administration of C134 in Patients With Recurrent GBM (C134-HSV-1) | terminated | Phase 1 | 1 | University of Alabama at BirminghamOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT04869449 | Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas | terminated | Early Phase 1 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05553522 | Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer | terminated | Phase 1 | 1 | Baptist Health South FloridaOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT06098248 | Evaluation of cCeLL-Ex Vivo Confocal Microscopy for Real-time Brain Tumor Diagnosis(cCeLLExvivo) | terminated | N/A | 285 | VPIX MedicalINDUSTRY | 2 | Dec 15, 2025 | clinicaltrials |
| NCT04106531 | Validation of a Quality of Life Metric "Prolac-10"(Prolac-10) | terminated | — | 8 | Ohio State UniversityOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT04964960 | Pembro+Chemo in Brain Mets | terminated | Phase 2 | 3 | John L. Villano, MD, PhDOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT03904862 | Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery | terminated | Phase 1 / Phase 2 | 21 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Oct 30, 2025 | clinicaltrials |
| NCT03396575 | Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I)(BRAVO) | terminated | Phase 1 | 11 | University of FloridaOTHER | 1 | Oct 29, 2025 | clinicaltrials |
| NCT04402073 | Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma(PersoMed-I) | terminated | Phase 2 | 20 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 8 | Oct 23, 2025 | clinicaltrials |
| NCT04543188 | A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement | terminated | Phase 1 | 65 | PfizerINDUSTRY | 3 | Oct 23, 2025 | clinicaltrials |
| NCT04712721 | Study of [68Ga]-FF58 in Patients With Selected Solid Tumors Expected to Overexpress αvβ3 and αvβ5 Integrins. | terminated | Early Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT01849952 | Evaluating the Expression Levels of MicroRNA-10b in Patients With Gliomas | terminated | — | 94 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT04462419 | 18F-fluciclovine PET/MRI Imaging for the Detection of Tumor Recurrence After Radiation Injury to the Brain | terminated | — | 19 | Mayo ClinicOTHER | 1 | Sep 10, 2025 | clinicaltrials |
| NCT03149575 | VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM(STAR-3) | terminated | Phase 3 | 2 | DelMar Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT04074785 | Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6(SCCC-06319) | terminated | Early Phase 1 | 10 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT03330197 | A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG | terminated | Phase 1 / Phase 2 | 6 | Alaunos TherapeuticsINDUSTRY | 1 | Aug 12, 2025 | clinicaltrials |
| NCT03698162 | Precise DCE-MRI in Diagnosing Participants With Recurrent High Grade Glioma or Melanoma Brain Metastases | terminated | N/A | 15 | University of Southern CaliforniaOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT05554159 | A Virtually Delivered Exercise Intervention To Mitigate Cognitive Deficits From Radiotherapy In AYAs With Brain Tumors | terminated | N/A | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06038760 | Prospective Evaluation of AI R&D Tool in Adult Glioma and Other Primary Brain Tumours (PEAR-GLIO)(PEAR-GLIO) | terminated | — | 12 | Ourotech, Inc.INDUSTRY | 1 | Jul 30, 2025 | clinicaltrials |
| NCT04474925 | Pre- Versus Post-operative SRS for Resectable Brain Metastases | terminated | Phase 3 | 8 | AHS Cancer Control AlbertaOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT04239092 | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | terminated | Phase 1 | 40 | Actuate Therapeutics Inc.INDUSTRY | 1 | Jul 17, 2025 | clinicaltrials |
| NCT04461418 | Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases(ACT-FAST) | terminated | Phase 2 | 2 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04804709 | Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) | terminated | Phase 1 | 5 | Columbia UniversityOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT01430351 | Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy | terminated | Phase 1 | 144 | M.D. Anderson Cancer CenterOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT03593330 | Neurosurgical Transitional Care Programme(TCP) | terminated | N/A | 242 | Barts & The London NHS TrustOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT04897880 | A Study of Panobinostat in Pediatric Patients With Solid Tumors Including MRT/ATRT(NORTH) | terminated | Phase 2 | 25 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 3 | Feb 24, 2025 | clinicaltrials |
| NCT03416530 | ONC201 in Pediatric H3 K27M Gliomas | terminated | Phase 1 | 134 | Jazz PharmaceuticalsINDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT01551680 | A Trial Evaluating Concurrent Whole Brain Radiotherapy and Iniparib in Multiple Non Operable Brain Metastases(RAPIBE) | terminated | Phase 1 | 3 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04047602 | Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study(RADREMI) | terminated | N/A | 18 | Indiana UniversityOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT01814813 | Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | terminated | Phase 2 | 90 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT03276676 | [18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors | terminated | Phase 1 / Phase 2 | 10 | University of UtahOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT02525692 | Oral ONC201 in Adult Recurrent Glioblastoma | terminated | Phase 2 | 84 | Jazz PharmaceuticalsINDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT04771897 | A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)(KONQUER) | terminated | Phase 1 | 10 | Bexion Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04525014 | RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors(PIRATE) | terminated | Phase 1 | 2 | EpicentRx, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT01246869 | Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water | terminated | Phase 1 | 2 | University of UtahOTHER | 1 | Oct 1, 2024 | clinicaltrials |
Data updated 4 days agoSource updated Sep 23, 2026source: clinicaltrials